NCT01932762View on ClinicalTrials.gov

Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

December 4, 2014

Study Completion Date

December 4, 2014

Conditions

Hepatitis C

Interventions

DRUG

Grazoprevir

100 mg every day (QD) orally

DRUG

Elbasvir

50 mg QD orally

DRUG

Ribavirin

Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01932762 - Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) | Biotech Hunter | Biotech Hunter